Literature DB >> 23407438

Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin.

Sascha Lange1, Christoph Fraune, Natalia Alenina, Michael Bader, A H Jan Danser, Anne-Roos Frenay, Harry van Goor, Rolf Stahl, Genevieve Nguyen, Edzard Schwedhelm, Ulrich Otto Wenzel.   

Abstract

BACKGROUND AND
OBJECTIVE: The antihypertensive effects of the direct renin inhibitor aliskiren last substantially longer after treatment withdrawal than expected based upon its plasma half-life. This may be attributable to drug accumulation in the kidney as recently shown in rats and mice. Since aliskiren binds to renin we examined in the present study whether this accumulation depends on the renin content of the kidney.
METHODS: For this we measured the aliskiren concentration in the kidney of wild-type as well as AT1a receptor(-/-) and Ren1c(-/-) mice. AT1a receptor(-/-) mice overexpress renin due to the lack of angiotensin II-mediated negative feedback, whereas Ren1c(-/-) mice lack renal renin expression.
RESULTS: Accumulation of aliskiren was found in the kidney of wild-type mice. However, renal accumulation was neither influenced by the overexpression nor by the absence of renin in the kidney. It was recently shown that the effects of aliskiren can be blocked by a handle region peptide, which inhibits the nonproteolytic activation of prorenin bound to the (pro)renin receptor. To investigate whether this putative (pro)renin receptor blocker influences renal aliskiren accumulation, we administered the blocker in addition to aliskiren. No influence on renal aliskiren accumulation was observed.
CONCLUSION: These data confirm accumulation of aliskiren in the murine kidney and demonstrate that neither renin nor (pro)renin receptor-bound prorenin are major players in this process.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23407438     DOI: 10.1097/HJH.0b013e32835e226b

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

1.  Renal angiotensin-converting enzyme upregulation: a prerequisite for nitric oxide synthase inhibition-induced hypertension?

Authors:  Lodi C W Roksnoer; Ewout J Hoorn; A H Jan Danser
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

2.  Aliskiren increases aquaporin-2 expression and attenuates lithium-induced nephrogenic diabetes insipidus.

Authors:  Yu Lin; Tiezheng Zhang; Pinning Feng; Miaojuan Qiu; Qiaojuan Liu; Suchun Li; Peili Zheng; Yonglun Kong; Moshe Levi; Chunling Li; Weidong Wang
Journal:  Am J Physiol Renal Physiol       Date:  2017-02-22

Review 3.  Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.

Authors:  Carlos M Ferrario; Adam E Mullick
Journal:  Pharmacol Res       Date:  2017-05-29       Impact factor: 7.658

4.  Adaptive immunity and IL-17A are not involved in the progression of chronic kidney disease after 5/6 nephrectomy in mice.

Authors:  Alva Rosendahl; Reza Kabiri; Marlies Bode; Anna Cai; Stefanie Klinge; Heimo Ehmke; Hans-Willi Mittrücker; Ulrich O Wenzel
Journal:  Br J Pharmacol       Date:  2018-12-18       Impact factor: 8.739

Review 5.  From ARB to ARNI in Cardiovascular Control.

Authors:  Estrellita Uijl; Lodi C W Roksnoer; Ewout J Hoorn; A H Jan Danser
Journal:  Curr Hypertens Rep       Date:  2016-12       Impact factor: 5.369

6.  Feasibility of fluorescence energy transfer system for imaging the renoprotective effects of aliskiren in diabetic mice.

Authors:  Kengo Kidokoro; Minoru Satoh; Seiji Itano; Atsunori Kuwabara; Tamaki Sasaki; Naoki Kashihara
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-05-23       Impact factor: 1.636

7.  Aliskiren and the dual complement inhibition concept.

Authors:  Maria Vanessa Perez-Gomez; Alberto Ortiz
Journal:  Clin Kidney J       Date:  2019-10-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.